AbbVie's 'Unjustified' Humira Settlements Divide Market, Class Action Claims
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.
You may also be interested in...
Unlikely Foe Gets AbbVie To Alter Humira Marketing Practices In California
Under $24m settlement with the California Department of Insurance, AbbVie’s nurse ‘ambassadors’ cannot participate in conversations between patients and insurance companies and must disclose that they are paid by the company.
BsUFA III: Could Regulatory Science Research Emerge With Other Tweaks?
Meeting management and some application assessment changes also may be necessary as stakeholders prepare for the second biosimilar user fee program reauthorization.
Playing It Safe? Hahn's Biosimilar View
US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?